Core Viewpoint - The procurement qualification of Zhejiang Jinhua Kang'enbei Biopharmaceutical Co., Ltd. for acetylcysteine effervescent tablets has been suspended due to non-compliance with regulations as per the announcement from the Shanghai Sunshine Pharmaceutical Procurement Network and the National Medical Products Administration [1][2]. Group 1: Company Performance - In the first half of 2025, Kang'enbei achieved operating revenue of 859 million yuan and net profit of 53.93 million yuan, accounting for 25.58% and 15.25% of Kang'enbei Pharmaceutical's total revenue and net profit respectively [1]. - The acetylcysteine effervescent tablets are a key product for Kang'enbei, with sales revenue of approximately 300 million yuan in 2022 and an estimated 350 million yuan in 2023, representing over 5% of total revenue for the year [2]. Group 2: Regulatory Issues - The National Medical Products Administration reported that one batch of acetylcysteine effervescent tablets produced by Kang'enbei did not meet regulatory standards, specifically regarding its characteristics [1]. - The suspension of procurement qualifications affects not only Kang'enbei but also 16 other companies, indicating a broader issue within the pharmaceutical industry regarding compliance with drug regulations [4]. Group 3: Market Impact - Kang'enbei's main business revenue in the first half of 2025 was 3.315 billion yuan, a year-on-year decrease of 2.68%, influenced by the failure to win bids in national procurement for acetylcysteine effervescent tablets and price reductions in other products [2].

Group 1 - Dematech won a 900 million yuan overseas smart logistics project from a well-known e-commerce giant in Latin America, focusing on intelligent logistics cross-belt sorting systems and related services [1] - Kang En Bei received approval for the registration of short-term financing bonds and medium-term notes, with a total registration amount of 1 billion yuan, valid for two years [1][2] - Zhi Xiang Jin Tai's GR1803 injection for systemic lupus erythematosus clinical trial has been approved by the National Medical Products Administration [2] Group 2 - Jin Da Wei's subsidiary received approval for a veterinary drug product, pyridone, valid from September 3, 2025, to September 2, 2030 [4] - Fu Li Wang's subsidiary plans to invest 500 million yuan in a high-end wire material project, focusing on high-strength prestressed steel strands for various applications [5] - He Li Biological's subsidiary's Class III medical device registration application has been accepted, focusing on natural bone repair materials [12] Group 3 - Lin Yang Energy won a 244 million yuan metering equipment project from Southern Power Grid, expected to positively impact its 2025 and 2026 performance [20] - Sanxia Water plans to absorb its wholly-owned subsidiary, Chongqing Changdian United Energy, with all assets and liabilities to be inherited by Sanxia Water [13] - Tian Cheng Technology canceled the use of 91 million yuan of raised funds for permanent working capital, ensuring no impact on the normal operation of investment projects [24] Group 4 - Baosteel received approval to publicly issue bonds totaling 20 billion yuan to professional investors, valid for 24 months [52] - Tian Kang Biological reported a 10.15% year-on-year increase in pig sales in August, with a total of 263,800 pigs sold [53] - Xinjiang Construction won multiple major projects totaling 4.506 billion yuan, including a 2.4 billion yuan photovoltaic hydrogen synthesis project [18]

证券代码：600572 证券简称：康恩贝 公告编号：临 2025-047 浙江康恩贝制药股份有限公司 关于超短期融资券和中期票据获准注册的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 浙江康恩贝制药股份有限公司（以下简称"公司"）为进一步拓宽公司融资渠道， 降低财务成本，优化公司债务结构，满足公司经营发展需要，根据《公司法》《银 行间债券市场非金融企业债务融资工具管理办法》等法律、法规的规定，经 2025 年 5 月 23 日召开的公司 2024 年度股东大会审议通过，同意公司向中国银行间市场 交易商协会（以下简称"交易商协会"）申请注册发行总额不超过（含）人民币 10 亿元的超短期融资券和总额不超过（含）人民币 10 亿元的中期票据，所募集资金用 于补充营运资金、置换金融机构借款和到期债务融资工具等及交易商协会认可的其 他用途。根据股东大会决议，公司向交易商协会提交了注册报告。近日，公司收到 交易商协会出具的《接受注册通知书》（中市协注[2025]SCP252 号）、（中市协注 [2025]MTN850 号），交易商 ...

Core Viewpoint - 康恩贝 has received approval from the trading association for the registration of its short-term financing bonds and medium-term notes, indicating a positive step for the company's financing activities [1] Group 1 - 康恩贝 has been granted a registration amount of 1 billion yuan for its short-term financing bonds [1] - The company has also received a registration amount of 1 billion yuan for its medium-term notes [1]

Core Points - The company, Kangnbei (600572.SH), has received a registration notice from the trading association for its short-term financing bonds and medium-term notes [1] - The registered amount for the short-term financing bonds is 1 billion yuan, and for the medium-term notes, it is also 1 billion yuan [1]

Core Viewpoint - Kang En Bei's wholly-owned subsidiary, Jinhua Kang En Bei, has received approval from the National Medical Products Administration for the inhaled compound ipratropium bromide solution, which is intended for patients requiring multiple bronchodilators [2] Company Summary - The approved drug is designed for patients who need a combination of various bronchodilators [2]

Core Viewpoint - Kang En Bei (600572) announced the approval of its inhaled compound ipratropium bromide solution by the National Medical Products Administration, indicating a significant advancement in its product portfolio for treating airway obstructive diseases [1] Group 1 - The product is intended for patients requiring multiple bronchodilators for the treatment of reversible bronchospasm related to airway obstructive diseases [1]

Group 1 - The core point of the article is that Kang En Bei has received approval from the National Medical Products Administration for its inhalation solution containing compound ipratropium bromide, which is intended for patients requiring multiple bronchodilators for the treatment of reversible bronchospasm related to obstructive airway diseases [1] - The product is expected to address a market demand, with projected sales in the domestic retail and medical terminal market amounting to 240 million yuan in 2024 [1]

证券简称：康恩贝 证券代码：600572 编号：2025-046 浙江康恩贝制药股份有限公司 关于子公司吸入用复方异丙托溴铵溶液 获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 内容的真实性、准确性和完整性承担法律责任。 近日，浙江康恩贝制药股份有限公司（以下简称"公司"）全资子公司浙江金华康恩 贝生物制药有限公司（以下简称"金华康恩贝"）收到国家药品监督管理局（以下简称" 国家药监局"）核准签发的吸入用复方异丙托溴铵溶液《药品注册证书》，现将相关情况公 告如下： 上市许可持有人：金华康恩贝 批准文号：国药准字 H20255282 证书编号：2025S02669 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 吸入用复方异丙托溴铵溶液由勃林格殷格翰药业有限公司开发，于 1994 年 12 月在法 国首次获批上市，并于 1996 年和 1998 年分别在美国、德国上市。2006 年 10 月，商品名 为 Combivent®（可必特）的吸入用复方异丙托溴 ...

康恩贝9月8日公告，公司全资子公司浙江金华康恩贝生物制药有限公司获得国家药品监督管理局核准签 发的吸入用复方异丙托溴铵溶液《药品注册证书》。公司将积极安排该品种的生产上市，预计将对公司 业绩产生积极影响。但因受国家政策、市场环境等因素影响，未来产品销售及收入存在不确定性。 ...